Physiomics plc (AIM: PYC) announced on Monday that it has secured a contract with a UK-based biotech company developing antibody-drug conjugate (ADC) therapies for hard-to-treat cancers.

The GBP102,000 project will run from April to August 2025 and focus on developing a pharmacokinetic (PK) and pharmacodynamic (PD) model to optimise dosing for the client's First-in-Human trial.

As a leader in mathematical modelling, data science and biostatistics, Physiomics supports biotech and pharma firms in streamlining drug development.

Leveraging its proprietary Virtual Tumour technology and computational expertise, the company has contributed to over 100 commercial projects, collaborating with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.